# A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors

> **NCT07509684** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Anglikang Pharmaceutical Co., Ltd.** · enrollment: 190 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ALK-N001 for Injection

## Key facts

- **NCT ID:** NCT07509684
- **Lead sponsor:** Zhejiang Anglikang Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-12
- **Final completion:** 2029-06
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07509684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07509684, "A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07509684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*